InterWest Health Providing its Members Access to Genetic Technologies' Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with InterWest Health to provide the preferred provider organization's members access to GTG's BrevaGen breast cancer diagnostic test.

The deal is the eighth that Melbourne, Australia-based GTG has reached with a US PPO. The deal was forged between its wholly owned subsidiary Phenogen Sciences and InterWest, a regional provider network based in Missoula, Mont. servicing seven states in the northwest US. InterWest's network includes more than 15,000 health care providers, GTG said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.